195 related articles for article (PubMed ID: 17454196)
1. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Sirohi B; Cunningham D; Norman A; Last K; Chau I; Horwich A; Oates J; Chong G; Wotherspoon A
Hematology; 2007 Apr; 12(2):149-53. PubMed ID: 17454196
[TBL] [Abstract][Full Text] [Related]
2. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
4. R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Kühnl A; Peckitt C; Patel B; Ardeshna KM; Macheta MP; Radford J; Johnson R; Paneesha S; Barton S; Chau I; Begum R; Valeri N; Wotherspoon A; Du Y; Zerizer I; Cunningham D
Ann Hematol; 2020 Jan; 99(1):105-112. PubMed ID: 31776726
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
6. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
[TBL] [Abstract][Full Text] [Related]
7. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
Yim KL; Ashley S
Med Oncol; 2012 Dec; 29(5):3535-9. PubMed ID: 22825684
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
[TBL] [Abstract][Full Text] [Related]
10. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman AR; Wotherspoon A; Catovsky D
Br J Cancer; 2005 Apr; 92(8):1352-7. PubMed ID: 15812553
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
13. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.
Fenske TS; Hari PN; Carreras J; Zhang MJ; Kamble RT; Bolwell BJ; Cairo MS; Champlin RE; Chen YB; Freytes CO; Gale RP; Hale GA; Ilhan O; Khoury HJ; Lister J; Maharaj D; Marks DI; Munker R; Pecora AL; Rowlings PA; Shea TC; Stiff P; Wiernik PH; Winter JN; Rizzo JD; van Besien K; Lazarus HM; Vose JM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1455-64. PubMed ID: 19822306
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
Witzens-Harig M; Memmer ML; Dreyling M; Hess G
BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
[TBL] [Abstract][Full Text] [Related]
15. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
[TBL] [Abstract][Full Text] [Related]
18. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
[TBL] [Abstract][Full Text] [Related]
19. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Kewalramani T; Zelenetz AD; Nimer SD; Portlock C; Straus D; Noy A; O'Connor O; Filippa DA; Teruya-Feldstein J; Gencarelli A; Qin J; Waxman A; Yahalom J; Moskowitz CH
Blood; 2004 May; 103(10):3684-8. PubMed ID: 14739217
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
